Allogene Invested Capital from 2010 to 2025
| ALLO Stock | USD 2.02 0.09 4.66% |
Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
Allogene |
About Allogene Therapeutics Financial Statements
Allogene Therapeutics investors utilize fundamental indicators, such as Invested Capital, to predict how Allogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people.
Check out the analysis of Allogene Therapeutics Correlation against competitors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.